Belite Bio, Inc (BLTE)
Market: NASD |
Currency: USD
Address: 12750 High Bluff Drive
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Show more
📈 Belite Bio, Inc Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$85.00
-
Upside/Downside from Analyst Target:
40.82%
-
Broker Call:
10
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Belite Bio, Inc
| Date | Reported EPS |
|---|
| 2025-03-17 | -0.32 |
| 2024-11-12 | -0.28 |
| 2024-08-09 | -0.31 |
| 2024-08-08 | -0.31 |
| 2024-05-13 | -0.27 |
| 2024-05-13 | -0.27 |
| 2024-03-11 | -0.25 |
| 2024-03-11 | -0.25 |
| 2023-11-13 | -0.4 |
| 2023-11-13 | -0.4 |
| 2023-08-08 | -0.26 |
| 2023-08-08 | -0.26 |
| 2023-05-10 | - |
| 2023-05-09 | - |
| 2023-03-31 | - |
| 2023-03-30 | - |
| 2022-08-10 | - |
| 2022-08-09 | - |
| 2022-04-29 | - |
| 2022-04-28 | - |
📰 Related News & Research
No related articles found for "belite bio".
